inc buy pt celsiu heat temperatur rise initi coverag
buy rate price analyst anthoni vendetti full summari
 hold share reach price downgrad hold wait car-t
beigen ltd bgne buy pt tislelizumab move third global phase program- esophag
cancer rais pt analyst jason kolbert full summari
nic inc hold loss texa portal contract pressur ep remov price target maintain hold
intevac inc ivac buy pt odlc adopt sku top smartphon oem signific posit
atossa genet inc ato buy pt addit find present endoxifen studi call webcast
mesoblast ltd meso buy pt rise revenu fall burn rate prepar could signific
 buy pt beat focu shift tripl approval/
launch tez/iva pdufa februari analyst jason mccarthi ph full summari
corpor event call maxim salesperson inform
unit health product inc ueec ndr nyc ceo doug beplat wed thu feb
landec corpor cover vendetti ndr boston cfo greg skinner tue feb
dineequ inc cover ndr san francisco ceo stephen joyc interim cfo gregori
kalvin execut director ir ken dipte mon feb
cover ndr boston cfo golder wed jun
saratoga invest corp sar cover diana ndr nyc ceo chri oberbeck cfo henri steenkamp
presid mike grisiu thur feb
keyw hold corp keyw cover kinstling ndr san francisco ceo weber wed thu feb
nic inc cover kinstling ndr nyc cfo steve kovzan vice-president corpor commun
corp cover kinstling ndr boston cfo ranjan kalia wed
celsiu heat temperatur rise
initi coverag buy rate price target
celsiu differenti energi drink brand product
back clinic studi suggest consumpt lead increas
calori burn weight loss
net revenu grew y/i project acceler y/i
follow greater y/i growth next two year
believ us busi cash flow posit driven outsiz growth
key distribut channel retail fit e-commerc
expect invest heavili intern expans notabl
china repres major growth opportun opinion
initi coverag inc buy rate
month price target develop market sell function energi
fit drink beverag back clinic studi show consumpt
lead improv metabol increas calorie-burn rate combin
exercis higher rate fat loss muscl mass gain
differenti product energi drink market grow significantli faster
overal energi drink market specif net revenu grew y/i
project acceler y/i follow greater y/
growth follow two year view continu out-performance
primarili due celsiu key differenti energi drink weight loss relat
function benefit also address key aspect health well trend
opinion offer sugar-fre beverag contain numer vitamin
miner well all-natur product line
us busi experienc acceler growth domest revenu growth
acceler y/i estim
believ varieti function benefit offer across three product
line appeal divers consum base reach numer
distribut channel illustr fact first three quarter
domest revenu grew y/i retail account y/i health
fit account y/i e-commerc account expect us sale growth
remain strong continu target consum health-focus lifestyl
frequent locat gym natur groceri store
asia repres major growth opportun asia-pacif expect fastest-
grow market energi drink well-posit
capit trend recent launch singapor hong kong china
maintain crucial strateg relationship area includ asia-bas
watson group privat oper retail store run major
sharehold li ka-sh qifeng food privat maintain
network distributor region manag project break-even new
geograph launch three year expect use cash gener
profit busi us sweden fund recent
privat placement support expans highli attract region
compel valuat share current trade ev/
revenu estim compar peer averag respect
deriv price target employ dcf analysi discount
rate perpetu growth rate target impli share trade
ev/revenu estim premium peer believ justifi due
differenti product above-p revenu growth us signific
intern expans opportun east asia
click full note
beat focu shift tripl
approval/launch tez/iva pdufa februari
vertex report cf cystic fibrosi revenu beat
consensu kalydeco revenu vs consensu
orkambi revenu vs consensu total cf
revenu repres y/i increas non-
oper expens cash end
year non-gaap ep beat consensu
guidanc vertex guid non-gaap oper expens
increas due advanc clinic program cf
support upcom tez/iva launch pdufa februari
compani provid cf revenu guidanc tez/iva approv
expect continu growth vertex provid guidanc
revenu assumpt remain continu reimburs orkambi
ex-u kalydeco label expans launch tez/iva drive
revenu growth vs growth model assum
opex low end guidanc point non-gaap
ep higher opex could mean slightli lower ep estim
depend launch trajectori tez/iva view recal orkambi
gener first two quarter launch
full year assumpt tez/iva may conserv
orkambi-lik launch tez/iva would
off-set higher opex potenti mean even stronger bottom line
tripl ahead vertex plan advanc two tripl combin next-
gen corrector phase program review
conclus vertex beat consensu base continu growth
kalydeco orkambi expect continu focu
turn launch tez/iva pend approv
follow europ approv expect addit tripl combin
far behind could posit vertex captur
tripl combin phase program vertex plan advanc two tripl
combin next-gen corrector
phase
program target homozygot minim function
heterozygot combin tezacaftor/ivacaftor
combin tezacaftor studi expect
initi follow decis advanc
pivot program base data two on-going studi
demonstr percent predict forc expiratori volum
respect sweat chlorid significantli reduc day
respect mean absolut chang respiratori
domain cfq-r day rang depend dose
rang
tezacaftor/ivacaftor doublet nda tez/iva children age older
homozygot least one residu function
mutat one copi heterozygot file pdufa date
februari ema european medicin agenc valid tez/iva
applic approv eu expect
click full note
share reach price downgrad hold
wait car-t data
share nearli doubl past week reach week
high fundament believ compani could
signific valu car-t space stand-alone car-t player becom
scarc seen data yet histor
valu compani base stem cell program wait
data earli trial incorpor car-t model
taken advantag increas valuat two privat
placement gener combin good move view first
rais decemb share second rais
announc januari gross proce share
factor rais forecast compani
cash current burn rate per quarter extend
runway
conclus look forward data
car-t studi posit would posit compani becom
car-t player could add even upsid stock
posit view compani princip lack data share
price reach target without data strong
ration rais valuat remov price target
downgrad share hold buy clariti
car-t program investor note regen side
busi cell therapi knee longer part focu
car-t program recal previous expect report top-line data
studi believ data repres
critic inflect point stock releas howev find uncertainti around
timelin concern
studi china-bas single-sit single-arm dose-
escal trial three patient cohort cohort consist three patient
treat escal dose cell evalu safeti efficaci
cell persist patient r/r dlbcl diffus larg cell
lymphoma data translat larger trial
studi car-t acut lymphoblast leukemia
studi china chines hospit plagh beij initi
dose-escal studi use optim proprietari
construct chimer antigen receptor t-cell car-t therapi
patient relaps refractori r/r b-cell acut lymphoblast
leukemia studi evalu safeti efficaci persist
cell like studi studi use trial
design escal dose cell evalu safeti efficaci cell
click full note
odlc adopt sku top smartphon oem
result in-lin revenu guidanc ahead estim though
modestli consensu
increment color odlc adopt top smartphon oem give us
increas confid inflect vertex order transpir continu
maintain conserv view time
reiter buy rate price target estim
result in-lin revenu guidanc ahead estim though modestli
consensu ivac report dec revenu in-line prior
consensu gm vs consensu thu ep
vs consensu above-consensu result driven better
guidanc ep guidanc well
consensu estim estim
delta rel estim less lean tool asp vertex tool
asp surpris given lumpi capit equip industri
manag guid overal revenu increas least y/i
prior estim though consensu estim
build overal revenu guidanc consist flat photon revenu
flat hdd revenu growth solar growth
vertex tool tool least tool gm guidanc
estim consensu drive
ep estim slightli
increment color odlc adopt top smartphon oem give us
increas confid inflect vertex order transpir continu
maintain conserv view time manag note top smartphon
oem introduc market next coupl month phone
util ivac optic diamond like carbon odlc film protect decor film
stack backsid glass phone mean like wirelessli chargeabl
current phone util glass back phone decor film stack creat
color includ iphon use vacuum deposit non-conduct metal
oxid film stack phone-fac side backsid glass howev
color come behind glass vibranc clear color come
glass howev without scratch resist coat ivac odlc
protect color film bring color film stack outsid would result unsightli
color chip ivac manag expect odlc coat introduc
singl sku initi pend market respons would drive util ivac
odlc sku manag current project smartphon oem
vertex custom opportun odlc partner truli opto-electron
privat procur enabl ivac book vertex tool
compar prior expect vertex tool recogn revenu
would flat given color win smartphon oem
guidanc tool increas confid time
inflect vertex order ivac recogn revenu tool
reiter buy rate price target estim
unchang leav time inflect vertex order
thu estim unchang includ revenu
ep price target base multipl
ep estim discount back
click full note
loss texa portal contract pressur ep
remov price maintain hold
compani confer call yesterday post-clos manag
announc award payment process piec texa
procur softwar servic procur renew
texa repres total revenu estim
softwar servic repres payment process
also believ payment process revenu much lower margin
softwar servic revenu
lose contract state past manag abl
rightsiz cost structur quickli limit impact profit
expect softwar revenu texa complet end
revis estim ep
includ estim drop tax rate
share follow result remov price
target maintain hold rate inform releas relat
texa
loss texa softwar servic contract major blow
accord septemb texa repres total revenu
manag yet abl share inform estim softwar
servic texa repres revenu million
annual furthermor payment process texa estim
revenu gener lower margin given servic commodit
high fix fee interchang result remain
texa revenu lead lower overal gross margin despit manag like
abl quickli rightsiz texa overhead
offici award expect march accord texa repres
award expect manag host confer call provid
guidanc detail texa current texa gov contract run
see opportun outsid state growth off-set declin
texa manag confirm activ statewid procur though
remain discuss state win piec work state
provid modest increment revenu case illinoi
expect possibl new statewid contract least month given
sale cycl case illinoi built platform gener
million revenu track gener anoth
ad million annual revenu addit award
contract feder level award produc immateri revenu
date
lower estim reflect texa mitig tax reform
estim ep includ lower revenu estim
million million reflect loss texa lower state
growth predict growth texa meantim modest declin
driver histori record revenu result lower oper
profit estim million million reduct off-set
chang effect tax rate assumpt expect
ep given reduct revenu texa
view manag need invest either drive growth expand new
market creat new avenu growth
result rel in-lin revenu million million higher
estim driven million revenu deliveri first phase
enterpris licens permit platform time illinoi revenu
uncertain therefor exclud estim second deliver
illinoi expect gener anoth revenu ep
lower estim lower gross margin
maintain hold rate remov price target share
indic follow result line estim
loss annual revenu percentag maintain hold rate remov price
target limit confid sustain recoveri stock limit
pipelin lack inform texa econom
click full note
tislelizumab move third global phase
program- esophag cancer rais pt
beigen announc initi global phase trial
tislelizumab partner celgen celg nr patient esophag
squamou cell carcinoma escc esophag cancer third global
pivot trial initi tislelizumab also evalu
non-smal cell lung cancer hepatocellular carcinoma china
tislelizumab two pivot trial relapsed/refractori hodgkin lymphoma
urotheli cancer
phase trial evalu tislelizumab vs
chemotherapi second-lin treatment advanc unresect
metastat escc patient primari endpoint studi overal
surviv secondari endpoint progression-fre surviv object
respons rate durat respons qualiti life safeti toler
recal beigen recent complet equiti financ
estim cash balanc sheet runway expect
launch btk inhibitor tislelizumab
factor non-recurring collabor revenu could
extend runway
model adjust base continu advanc tislelizumab
factor elimin risk cut therapeut model previous
net effect price target increas
conclus beigen continu expand teslilizumab pivot program
across multipl cancer type global partner celgen china
tislelizumab engin fc region differenti
antibodi checkpoint space view could becom first
human monoclon antibodi immun checkpoint
receptor beigen develop monotherapi
combin agent variou solid-organ blood-born cancer cell
surfac receptor play import role down-regul immun system
prevent activ certain type white blood cell call t-cell
specif t-cell becom activ t-cell begin up-regul
express receptor bind ligand receptor induc
transduct neg signal insid t-cell dampen immun respons
natur phenomenon checkpoint immun system use
care control fine-tun immun respons howev cancer cancer
cell upregul express ligand thu abil dampen
shut immun respons t-cell put brake anti-tumor
immun respons occur t-cell revert exhaust phenotyp
longer attack inhibitor remov blockad t-cell releas
brake degre express vari wide tumor type
teslelizumab clinic program beigen recent announc first patient
dose pivot clinic trial china tislelizumab
investig antibodi patient hepatocellular carcinoma
trial enrol patient treatment naiv unresect
januari patient trial esophag cancer initi patient
unresect metastat diseas recal also evalu
pivot trial china r/r hodgkin lymphoma urotheli cancer well
global trial nsclc bring number on-going pivot trial four
click full note
morn open enterpris product partner epd nr
announc first off-tak agreement plan ethylen export
termin jointli develop nvg
epd announc flint hill resourc base ethylen produc
major japanes trade firm first anchor client plan
mention prior note expect off-tak
agreement catalyst nvg share
base epd earn call morn financi invest decis
fid yet reach facil expect fid announc
come sometim epd expect facil develop
anoth locat houston ship channel rather morgan point
tax reason tax abat
view announc posit step nvg base
ethylen export facil limit long-term risk associ rate
highlight note publish juli nvg enterpris product
partner jointli develop ethylen export termin enterpris product partner
announc morn first off-tak agreement plan facil
base ethylen produc flint hill resourc privat major japanes trade
firm sign long-term agreement joint ventur base ethylen
export facil plan ethylen facil annual export capabl
million ton on-site refriger storag unit ton load rate
ton per hour furthermor support export facil number
pipelin storag facil connect possibl increas export
capabl benefici petrochem sector produc
market diversif rather sole reli polyethylen export market
 ethylen expans owe part increas shale reserv
aggreg ethylen product texa louisiana expect grow nearli
billion pound annual could open arbitrag opportun
off-tak agreement far east remind one ethylen export
termin houston ship channel nr export facil
financi invest decis fid although facil plan
develop epd morgan point marin export facil expect new
locat somewher within houston ship channel epd announc earn
call morn fid come soon chang locat due
tax reason facil still plan oper maintain earli
cargo ahead fulli complet facil could occur nvg vessel
could fulli chill cargo voyag
bottom line wait off-tak agreement announc help spur
nvg share although share move news believ
upsid recommend investor look long-term exposur
accumul share nvg therefor reiter buy rate price
target price target base multipl forward
click full note
addit find present endoxifen
atossa genet hold confer call tomorrow discuss addit
find phase studi oral endoxifen studi design
determin pharmacokinet properti endoxifen oral topic
form well safeti toler
preliminari result releas septemb octob studi
object met patient oral arm studi met exceed
atossa develop oral endoxifen prevent breast cancer
recurr base known data safeti efficaci
tamoxifen metabolit endoxifen mean potenti acceler
timelin approv
conclus atossa candid known drug publish safeti
efficaci profil de-risk view tamoxifen fulvestr
gener combin annual small portion market
point upsid current valuat car-t program could attract
partner repres addit upsid see multipl catalyst ahead
trial begin data emerg
endoxifen breast cancer prevent tamoxifen wide use select
estrogen receptor modul serm tamoxifen activ rather
metabol compound activ endoxifen bind
estrogen receptor er breast cancer cell inhibit growth estim
women poor metabol tamoxifen thu get sub-
therapeut dose endoxifen increas risk recurr atossa develop
oral formul endoxifen adjuv treatment patient refractori
tamoxifen studi oral endoxifen demonstr posit safeti profil
endoxifen level therapeut threshold
topic formul endoxifen develop mammograph breast
densiti mbd mbd increas risk develop cancer hide exist tumor
latter critic earli stage breast cancer could prevent
women receiv avail viabl therapi high cure rate
microcathet drug deliveri platform breast cancer could extend
car-t system deliveri wide use breast cancer drug like fulvestr result
side effect atossa patent microcathet deliveri platform mitig risk
via deliveri therapeut dose drug nippl directli
breast duct intraduct id tumor id fulvestr current trial
vs intramuscular inject fulvestr er ductal carcinoma situ phase i/ii
local invas breast cancer studi evalu safeti drug distribut hormon
receptor express effect lesion size atossa also initi preclin program
evalu use microcathet deliveri system car-t breast cancer
rational minim side effect like cytokin releas syndrom
maxim car-t target tumor
click full note
rise revenu fall burn rate prepar
could signific catalyst
mesoblast report chang cash posit decemb quarter fy
june net cash outflow oper includ
up-front payment tigenix tig nr mesoblast end period
cash equiti facil place
tigenix paid licens ip recal mesoblast recent gave tigenix freedom
oper global commerci compani adipos stem cell
product local treatment fistula addit
up-front payment receiv previou quarter tigenix pay million
within month million product regulatori mileston
addit mesoblast receiv singl digit royalti net sale
time shift focu catalyst mesoblast cash posit
suffici quarterli burn rate reach key inflect point
heart failur disc degener gvhd
gvhd open-label trial pediatr patient
steroid-refractori acut gvhd complet enrol
primari endpoint data day readout follow day
surviv data
heart failur hf studi class ii-iii hf
enrol patient track complet enrol
studi end-stag hf class iv complet
enrol data readout expect
disc degener dd studi expect
complet enrol earli studi evalu durabl
pain reduct function improv aim similar result
observ studi
studi
demonstr durabl efficaci anti-tnf refractori patient go
week total data use design program
conclus mesoblast continu make progress across multipl late-stag
regen medicin program data point expect
rest posit provid catalyst stock
view
heart failur program trial primari endpoint comparison recurr
heart failure-rel major advers cardiovascular event hf-mace advanc
congest heart failur chf patient receiv either cathet
inject left ventricular heart muscl sham control
expect patient advanc chf enrol date trial
enrol expect complet review patient data two time
point april octob trial data monitor committe maintain
recommend studi continu plan interim analysi
trial primari endpoint april first patient also success
trial clear continu decemb receiv
fda regen medicin advanc therapi design allow
multi-disciplinari comprehens interact fda support effici
develop potenti acceler approv pathway program well
elig prioriti review
click full note
maxim analyst coverag univers
